Trial By Error: CBT and Irritable Bowel Syndrome

Jonathan Edwards said:
Apparently it is Digital Therapeutic, i.e. an internet-based treatment.
Click to expand...

Thank you. I've never managed to remember those US abbreviations about diagnoses and treatments with an x on the end (Rx, Dx and ???), and yet most Americans use them without batting an eyelid about it. And I've never heard of a Digital Therapeutic treatment before either, so I learn something new every day. Unfortunately, I'll probably have forgotten what DTx means by bedtime. :banghead:
 
Arnie Pye said:
Thank you. I've never managed to remember those US abbreviations about diagnoses and treatments with an x on the end (Rx, Dx and ???), and yet most Americans use them without batting an eyelid about it. And I've never heard of a Digital Therapeutic treatment before either, so I learn something new every day. Unfortunately, I'll probably have forgotten what DTx means by bedtime. :banghead:
Click to expand...

As far as I was aware treatment was always Rx, not Tx. I suspect this DTx is a newfangled babblebungle.
 
well, now that the FDA has approved it, I think the issue will likely draw more interest from the realm of observers and readers outside Virology Blog. Matthew Holt (the guy who got the embargoed copy of the Mahana press release and tweeted out the thread about it) runs The Health Care Blog, which is well-read by health care professionals. His thing is bad digital stuff, which is how it caught his eye.
 
Jonathan Edwards said:
Yes he seemed to be saying that unlike you he does not trouble himself with the details of evidence quality, he just likes to call things crap when it suits him. And of course he does not want to slur anything like CBT if it might upset people.
Click to expand...

Well, from my e-mail exchanges with him, I don't think that's quite it. And in fact that does him a bit of a disservice, I think He recognizes that in this case the evidence is crap and cites me because I've done the analysis, but he's not surprised the evidence is crap because he sees most studies as being badly designed and providing little actionable data. In this case, he doesn't like basic things like online "advice" being monetized as if it's the same as talking to a human. He doesn't care about CBT one way or the other, whether to slur or not, and he's certainly doesn't seem concerned about upsetting anyone.
 
Trial by Error: FDA Approves Web-CBT for IBS; GET/CBT as Tomorrow’s “Rubbish”

Mahana set to announce FDA approval for ineffective IBS program

Earlier this year, I spent a lot of time blogging about the unethical and dishonest manner in which a San Francisco start-up called Mahana Therapeutics was promoting an eight-week web-based program of cognitive behavior therapy for patients suffering from irritable bowel syndrome. The company had recently licensed this product from King’s College London and was seeking marketing approval in the US and the UK.

I wrote multiple letters to company officials and medical advisers as well as key investigators to express my dismay about the way the findings were being hyped and thoroughly misrepresented. No one ever answered.
Click to expand...

https://www.virology.ws/2020/12/06/...ves-cbt-for-ibs-get-cbt-as-tomorrows-rubbish/
 
Mahana Therapeutics Obtains CE Mark for Parallel™ in the UK
First Prescription Digital Therapeutic to Reduce the Symptom Severity of Irritable Bowel Syndrome Also Receives NICE Recommendation

SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- Mahana Therapeutics, an emerging leader in prescription digital therapeutics, announced today that it has obtained a CE mark for its flagship product Parallel™. Parallel is the first prescription-only digital therapeutic (PDT) intended to reduce the severity of irritable bowel syndrome (IBS) symptoms in adult patients. The programme was developed in collaboration with expert researchers under the leadership of Professor Rona Moss-Morris, Ph.D, of King's College, London, and Professor Hazel Everitt, Ph.D, of the University of Southampton. Parallel has also been recommended for Evaluation in Practice by the National Institute for Health and Care Excellence (NICE).

IBS is a disorder of the gut-brain interaction. Parallel, formerly known as Regul8, was developed by a team of leading UK psychologists to teach adults cognitive behavioural therapy (CBT) skills to influence gut-brain communication. Parallel's three-month programme works by helping patients change certain behaviours and thoughts that can contribute to IBS and has been clinically proven to reduce the severity of IBS symptoms.

"We entered into this collaboration with Mahana because of our shared commitment to developing clinically validated, cost-effective treatment options that address IBS symptoms," said Professor Rona Moss-Morris, Professor of Psychology as Applied to Medicine and Head of Psychology at King's College, London, who led the development of the initial Parallel programme. "I am excited and proud that the result of our work together has met the high health and safety standards needed to obtain a CE mark."
Click to expand...
full press release
https://www.prnewswire.co.uk/news-r...mark-for-parallel-tm-in-the-uk-801248366.html
 
You must log in or register to reply here.
Back
Top Bottom